Pages that link to "Q33884461"

The following pages link to Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. (Q33884461):

Displaying 23 items.

• Gastrin in Gastrointestinal Diseases (Q33964563) (← links)
• Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties (Q34250142) (← links)
• Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation (Q36586589) (← links)
• From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial (Q36755148) (← links)
• Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients (Q37103342) (← links)
• Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms (Q37731335) (← links)
• Radiopharmaceutical development of radiolabelled peptides (Q37990399) (← links)
• Radiolabelled peptides for oncological diagnosis (Q37990405) (← links)
• Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates (Q38722877) (← links)
• Molecular imaging probes derived from natural peptides. (Q38748846) (← links)
• Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. (Q39512185) (← links)
• Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. (Q39552291) (← links)
• The in vivo disposition and in vitro transmembrane transport of two model radiometabolites of DOTA-conjugated receptor-specific peptides labelled with (177) Lu. (Q40364919) (← links)
• Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr (Q42780989) (← links)
• Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor. (Q52319422) (← links)
• Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. (Q55098217) (← links)
• Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression. (Q55263067) (← links)
• Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression (Q57757444) (← links)
• Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m (Q64230471) (← links)
• Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study (Q90100203) (← links)
• A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study (Q90273231) (← links)
• DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use (Q90366016) (← links)
• Identification of a suitable peptidic molecular platform for the development of NPY(Y1)R-specific imaging agents (Q97588200) (← links)